Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hydrocephalus that is present at birth.
No HPO annotations are available for this condition.
Age of onset: at birth.
L1 syndrome is seen almost exclusively in males. Affected Males L1 syndrome comprises three clinical phenotypes ranging from severe to mild; its major features are hydrocephalus, intellectual disability, spasticity of the legs, and adducted thumbs. To date, more than 280 individuals have been identified with a pathogenic variant in L1CAM . compares the features among the various phenotypes associated with L1 syndrome. It is important to note that all phenotypes can be observed within the same family. Table 2. L1 Syndrome: Comparison of Phenotypes in Male Probands by Select Features Feature | L1 Phenotype
L1 syndrome involves a phenotypic spectrum ranging from severe to mild. L1 syndrome should be suspected in individuals with any of the following clinical phenotypes or neuroimaging findings and supportive family history.
X-linked hydrocephalus with stenosis of aqueduct of Sylvius (HSAS). Signs present in affected males:
Source: GeneReviews — "L1 Syndrome"
No approved treatments are currently available for congenital hydrocephalus. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with L1 syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with L1 Syndrome
Table 5.
Recommended Surveillance for Individuals with L1 Syndrome
System/Concern | Evaluation | Frequency
| Neurologic eval | At regular intervals per individual patient
DD/ID
Spastic paraplegia
2 clinical trials registered. Interventions under study include procedural interventions and drug therapy. Pipeline includes 1 PHASE4, 1 NA. Research is primarily sponsored by academic and government institutions.
100 publications have been identified in PubMed for congenital hydrocephalus. Research spans Case Report / Case Series (26%), Review / Meta-Analysis (21%), and Epidemiology / Natural History (21%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 22 |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
HSAS | MASA syndrome,incl SPG1 | X-linked complicatedCC agenesis |
|---|---|---|
of aqueduct of Sylvius | 100% | Variable dilation ofthe 3rd ventricle |
CC agenesis/hypogenesis | +(accompanieshydrocephalus) | + in some |
Intellectual disability | Severe | Mild to moderate |
Delayed speech | + | + |
Spasticity of legs | + | + |
Adducted thumbs | 50% | 50% |
Source: GeneReviews — "L1 Syndrome"
The differential diagnosis of males with developmental delay or intellectual disability and early hypotonia evolving into spastic paraplegia during childhood, with or without adducted thumbs, includes many conditions. See OMIM Autosomal Dominant, Autosomal Recessive, and Nonsyndromic X-Linked Intellectual Developmental Disorder Phenotypic Series. Nonsyndromic congenital hydrocephalus. Individuals with L1 syndrome and hydrocephalus do not have major additional physical anomalies. Other single-gene causes of nonsyndromic congenital hydrocephalus include biallelic pathogenic variants in CCDC88C, MPDZ, and WDR8 (see OMIM PS236600). Nonsyndromic congenital hydrocephalus may also occur as part of (or secondary to) the following:
Source: GeneReviews — "L1 Syndrome"
Biomarker and diagnostic research for congenital hydrocephalus has been reported in the published literature.
System/Concern |
|---|
Evaluation |
|---|
Comment |
|---|
Brain malformation | Brain imaging study | MRI is preferred. |
Intellectual disability | Developmental eval | — |
Spasticity | Complete neurologic eval | — |
Adducted thumbs | Clinical observation | Hirschsprung disease |
association | Eval for Hirschsprung disease if there is history of constipation | — |
Genetic counseling | By genetics professionals1 | To inform patients families re nature, MOI, implications of L1 syndrome to facilitate medical personal decision making Family support/ resources |
Treatment of Manifestations in Individuals with L1 Syndrome Manifestation/Concern | Treatment | Considerations/Other |
Hydrocephalus | Surgical treatment as needed | Shunting of CSF is indicated to intracranial pressure.; Prenatal shunting offers no advantage . |
DD/ID | See . | Developmental outcome is variable individualized educational program is important. Spastic |
paraplegia | Standard treatment guidelines for spasticity should be followed. | Neurologic features should be monitored. Adducted |
thumbs | A splint may help degree of adduction. | Surgical intervention is not generally indicated.; In some milder cases, tendon transfer may improve thumb function. |
Source: GeneReviews — "L1 Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "L1 Syndrome"
2 trials found
Source: GeneReviews — "L1 Syndrome"
Estimated prevalence: Unknown (Unknown prevalence).
Research summaries | 18 | 21% |
Disease patterns and progression | 18 | 21% |
Laboratory research | 13 | 15% |
New treatment approaches | 5 | 6% |
Testing and diagnosis research | 4 | 5% |
Clinical study results | 4 | 5% |
Serpieri V (2026). [PMID: 41720098](https://pubmed.ncbi.nlm.nih.gov/41720098/). *Am J Hum Genet*. [Gene Therapy / Novel Therapeutics]
Anthony CS (2026). [PMID: 42156587](https://pubmed.ncbi.nlm.nih.gov/42156587/). *Neurosurg Rev*. [Review / Meta-Analysis]
Borni M (2026). [PMID: 41865987](https://pubmed.ncbi.nlm.nih.gov/41865987/). *World Neurosurg*. [Epidemiology / Natural History]
Sanker V (2026). [PMID: 41986703](https://pubmed.ncbi.nlm.nih.gov/41986703/). *Childs Nerv Syst*. [Review / Meta-Analysis]
Afshari FT (2026). [PMID: 41586628](https://pubmed.ncbi.nlm.nih.gov/41586628/). *Neurosurgery*. [Diagnostic / Biomarker]
Yang P (2026). [PMID: 41925876](https://pubmed.ncbi.nlm.nih.gov/41925876/). *Childs Nerv Syst*. [Epidemiology / Natural History]
Oria M (2026). [PMID: 41586625](https://pubmed.ncbi.nlm.nih.gov/41586625/). *Neurosurgery*. [Diagnostic / Biomarker]
Kim HK (2026). [PMID: 41370743](https://pubmed.ncbi.nlm.nih.gov/41370743/). *Neurology*. [Epidemiology / Natural History]
Darko K (2026). [PMID: 41670774](https://pubmed.ncbi.nlm.nih.gov/41670774/). *Childs Nerv Syst*. [Review / Meta-Analysis]
Doğan Arı AB (2026). [PMID: 40734719](https://pubmed.ncbi.nlm.nih.gov/40734719/). *Mol Syndromol*. [Epidemiology / Natural History]